Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: Associated with disease activity and vascular endothelial growth factor

Journal of Investigative Medicine

Volumn 61, Issue 5, 2013, Pages 848-851

  Li, Xiao Lin ^a   Lin, Tian Tian ^a   Qi, Chen Yue ^a   Yuan, Lin ^a   Xia, Li Ping ^a   Shen, Hui ^a   Lu, Jing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Ankylosing spondylitis; BASDAI; IL 33; SST2; VEGF

Indexed keywords

C REACTIVE PROTEIN; HLA B27 ANTIGEN; INFLIXIMAB; INTERLEUKIN 33; VASCULOTROPIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY;

ADULT; ARTHRITIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; EYE; FEMALE; HIP; HLA-B27 ANTIGEN; HUMANS; INFLAMMATION; INTERLEUKINS; MALE; RECEPTORS, CELL SURFACE; SOLUBILITY; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880954505     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31828deed2     Document Type: Article

References (20)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007; 369(9570): 1379-1390.
2. Brewerton DA, Hart FD, Nicholls A, et al Ankylosing spondylitis and HL-A 27. Lancet. 1973; 1(7809):904-907.
3. Braun J, Bollow M, Neure L., et al Use of immunohistological and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995; 38(4):499-505.
4. Mei Y, Pan F, Gao J., et al Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011; 30(2): 269-273.
5. Drouart M, Saas P, Billot M., et al High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol. 2003; 132(1):158-162.
6. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989; 258(2):301-304.
7. Hayakawa H, Hayakawa M, Kume A., et al Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007; 282(36):26369-26380.
8. Moulin D, Donzé O, Talabot-Ayer D, et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007; 40(3):216-225.
9. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4):361-368.
10. Wei JCC, Jan MS, Yu C.T., et al Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol. 2007; 26(5):739-742.
11. Hai H, Rudwaleit M, Braun J., et al Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis. 2005; 64(1):124-126.
12. Francois RJ, Gardner DL, Degrave E.J., et al Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum. 2000; 43(9):2011-2024.
13. Lu J, Kasama T, Kobayashi K., et al Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol. 2000; 164(11):5922-5927.
14. Lv HZ, Lin T, Xia L.P., et al Vascular endothelial growth factor gene polymorphisms and rheumatoid arthritis. J Investig Med. 2011; 59(3):593-598.
15. Talabot-Ayer D., McKee T, Gindre P., et al Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine. 2012; 79(1):32-37.
16. Theoharides TC, Zhang B, Kempuraj D., et al IL-33 augments substance PYinduced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A. 2010; 107(9):4448-4453.
17. Xu D, Jiang HR, Kewin P, et al IL-33 exacerbates antigen-induced arthritis by activating mast. Proc Natl Acad Sci U S A. 2008; 105(31):10913-10918.
18. Xiangyang Z, Lutian Y, Lin Z., et al Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine. 2012; 58(1):6-9.
19. Beltrán C.J., Núñez LE, Díaz-Jiménez D, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16(7):1097-1107
20. Mok MY, Huang FP, Ip W.K., et al Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology. 2010; 49(3):520-507.